GW677954 has not yet been approved in the US, EU or Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


GW677954 studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
ADG103440 DEVELOPMENT TERMINATED BY GSK II A Randomised, Double-blind, Parallel Group, Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of Oral GW677954 Capsules 2.5 mg, 5 mg, 10 mg and 20 mg a day for 24 Weeks in Overweight Dyslipidaemic Subjects.
ADG20001 DEVELOPMENT TERMINATED BY GSK II A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Study to Evaluate Efficacy, Safety and Tolerability of Oral GW677954 Capsules (2.5, 5, 10, 15 And 20 mg Once A Day) as a Monotherapy (Diet and/or exercise treated) or as an Add-On to Metformin for 16 Weeks Duration in Subjects with Type 2 Diabetes Mellitus